<--- Back to Details
First PageDocument Content
Pharmaceutical sciences / Design of experiments / Epidemiology / Pharmacology / Progression-free survival / Randomized controlled trial / Internet Relay Chat / Food and Drug Administration / Clinical trial / Research / Clinical research / Science
Pharmaceutical sciences
Design of experiments
Epidemiology
Pharmacology
Progression-free survival
Randomized controlled trial
Internet Relay Chat
Food and Drug Administration
Clinical trial
Research
Clinical research
Science

FOOD AND DRUG ADMINISTRATION

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 19,62 KB

Share Document on Facebook

Similar Documents

UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor

DocID: 1rgeq - View Document

Medical research / Clinical research / Research / Health / Clinical trials / Medical statistics / Design of experiments / Epidemiology / Surrogate endpoint / Analysis of clinical trials / Clinical endpoint / Progression-free survival

Guideline on CT in Small Populations - Adopted

DocID: 1qPMu - View Document

RTT / Brain tumor / Medical terminology / Medical physics / Cancer research / Response Evaluation Criteria in Solid Tumors / Imaging biomarker / Glioblastoma multiforme / Radiation therapy / Biomarker / Medical imaging / Progression-free survival

MayImproving Trial Success by Improving Tumor Assessment Jamal Gasmi, MD, PhD l Vice President & Global Leader Oncology & Hematology Drug Development, ICON Clinical Research James Conklin, MD, MS l Senior Vice Pre

DocID: 1pCHm - View Document

CHOP / Progression-free survival

Updated Results of Phase 1b of Tarextumab (TRXT, OMP-59R5, anti-Notch 2/3) in Combination with Etoposide and Platinum Therapy (EP) in Patients (pts) with Untreated Extensive-Stage Small Cell Lung Cancer (ED-SCLC) Copies

DocID: 1oRDd - View Document

Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunot

DocID: 1mrph - View Document